Mind + Muscle

technical minds + legal muscle


dig deep

Intas Pharmaceuticals Successfully Settles USITC Section 337 Investigation

  • 08.22.11
  • Sterne, Kessler, Goldstein & Fox P.L.L.C.

In March 2011, the United States International Trade Commission instituted a Section 337 investigation based upon a patent infringement complaint filed by Eli Lilly.  The complaint alleged that Sterne Kessler client -- Intas Pharmaceuticals Ltd. – imported and sold within the United States a generic version of Lilly’s anti-cancer drug Gemzar, which was made by a process patented by Lilly.   

On August 16, 2011, after expedited discovery was taken of all parties, Lilly and Intas entered into a successful settlement agreement that resolved all disputes in this investigation.  The investigation has been terminated by the Administrative Law Judge. 

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.